{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T09:35:24Z","timestamp":1774517724975,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.clcc.2021.09.002","type":"journal-article","created":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T22:35:56Z","timestamp":1631658956000},"page":"364-367","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Conversion Therapy With Encorafenib and Cetuximab for Chemo-Refractory BRAF V600E-Mutated Liver-Limited Colorectal Cancer Metastasis: The First Case Report"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6856-2593","authenticated-orcid":false,"given":"Maria Alessandra","family":"Calegari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brunella Di","family":"Stefano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Basso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmine","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Floriana","family":"Camarda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Ribelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annunziato","family":"Anghelone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaella","family":"Vivolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5647-0525","authenticated-orcid":false,"given":"Maria","family":"Bensi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Martini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmelo","family":"Pozzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Vellone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1596-2862","authenticated-orcid":false,"given":"Francesco","family":"Ardito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Salvatore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felice","family":"Giuliante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giampaolo","family":"Tortora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clcc.2021.09.002_bib0001","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.2217\/pgs.15.140","article-title":"BRAF in metastatic colorectal cancer: the future starts now","volume":"16","author":"Orlandi","year":"2015","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.clcc.2021.09.002_bib0002","doi-asserted-by":"crossref","first-page":"e711","DOI":"10.1111\/codi.12427","article-title":"BRAF mutation is associated with distinct clinicopathological characteristics in colorectal cancer: a systematic review and meta-analysis","volume":"15","author":"Clancy","year":"2013","journal-title":"Colorectal Dis"},{"key":"10.1016\/j.clcc.2021.09.002_bib0003","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1002\/cncr.28347","article-title":"Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases","volume":"119","author":"Karagkounis","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.clcc.2021.09.002_bib0004","doi-asserted-by":"crossref","first-page":"5843","DOI":"10.1158\/1078-0432.CCR-19-0863","article-title":"Mutation status of RAS, TP53, and SMAD4 is superior to mutation status of RAS alone for predicting prognosis after resection of colorectal liver metastases","volume":"25","author":"Kawaguchi","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clcc.2021.09.002_bib0005","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/SLA.0000000000002968","article-title":"Is hepatectomy justified for BRAF mutant colorectal liver metastases?: a multi-institutional analysis of 1497 patients","volume":"271","author":"Gagniere","year":"2020","journal-title":"Ann Surg"},{"key":"10.1016\/j.clcc.2021.09.002_bib0006","doi-asserted-by":"crossref","first-page":"5931","DOI":"10.1200\/JCO.2009.22.4295","article-title":"KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial","volume":"27","author":"Richman","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2021.09.002_bib0007","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1093\/annonc\/mdw645","article-title":"Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials","volume":"28","author":"Seligmann","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2021.09.002_bib0008","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejca.2019.06.008","article-title":"A validated prognostic classifier for (V600E)BRAF-mutated metastatic colorectal cancer: the 'BRAF BeCool' study","volume":"118","author":"Loupakis","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clcc.2021.09.002_bib0009","doi-asserted-by":"crossref","first-page":"e47054","DOI":"10.1371\/journal.pone.0047054","article-title":"The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis","volume":"7","author":"Safaee Ardekani","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.clcc.2021.09.002_bib0010","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1158\/2159-8290.CD-17-1226","article-title":"Combined BRAF, EGFR, and MEK inhibition in patients with BRAF(V600E)-mutant colorectal cancer","volume":"8","author":"Corcoran","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clcc.2021.09.002_bib0011","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clcc.2021.09.002_bib0012","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1200\/JCO.20.01994","article-title":"Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406)","volume":"39","author":"Kopetz","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2021.09.002_bib0013","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.20.02088","article-title":"Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study","volume":"39","author":"Tabernero","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2021.09.002_bib0014","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1038\/bjc.2015.142","article-title":"BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection","volume":"112","author":"Schirripa","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clcc.2021.09.002_bib0015","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.critrevonc.2015.12.015","article-title":"Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis","volume":"99","author":"Passiglia","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clcc.2021.09.002_bib0016","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/ijc.30089","article-title":"Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases","volume":"139","author":"Loes","year":"2016","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clcc.2021.09.002_bib0017","first-page":"e153","article-title":"Effect of KRAS and BRAF mutations on survival of metastatic colorectal cancer after liver resection: a systematic review and meta-analysis","volume":"16","author":"Tosi","year":"2017","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.clcc.2021.09.002_bib0018","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1038\/s41598-019-39328-6","article-title":"BRAF V600E and SRC mutations as molecular markers for predicting prognosis and conversion surgery in Stage IV colorectal cancer","volume":"9","author":"Shimada","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.clcc.2021.09.002_bib0019","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2018.0996","article-title":"Association of BRAF mutations with survival and recurrence in surgically treated patients with metastatic colorectal liver cancer","volume":"153","author":"Margonis","year":"2018","journal-title":"JAMA Surg"},{"key":"10.1016\/j.clcc.2021.09.002_bib0020","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ejca.2016.10.028","article-title":"Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: a pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest","volume":"73","author":"Cremolini","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clcc.2021.09.002_bib0021","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1038\/bjc.2017.334","article-title":"International consensus guidelines for scoring the histopathological growth patterns of liver metastasis","volume":"117","author":"van Dam","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clcc.2021.09.002_bib0022","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/PAS.0b013e31824057e7","article-title":"Infarct-like necrosis: a distinct form of necrosis seen in colorectal carcinoma liver metastases treated with perioperative chemotherapy","volume":"36","author":"Chang","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clcc.2021.09.002_bib0023","doi-asserted-by":"crossref","first-page":"S242","DOI":"10.1016\/j.annonc.2020.04.080","article-title":"ANCHOR CRC: a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E-mutant metastatic colorectal cancer","volume":"31","author":"Grothey","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2021.09.002_bib0024","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/s41571-021-00495-z","article-title":"Precision oncology in metastatic colorectal cancer - from biology to medicine","volume":"18","author":"Di Nicolantonio","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clcc.2021.09.002_bib0025","doi-asserted-by":"crossref","first-page":"S S243","DOI":"10.1016\/j.annonc.2020.04.484","article-title":"Encorafenib plus cetuximab with or without binimetinib for BRAFV600E metastatic colorectal cancer (mCRC): relationship between carcinoembryonic antigen (CEA) and clinical outcomes from BEACON CRC","volume":"31","author":"Grothey","year":"2020","journal-title":"Ann Oncol"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002821000888?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002821000888?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:07:56Z","timestamp":1761520076000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002821000888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S1533002821000888"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2021.09.002","relation":{},"ISSN":["1533-0028"],"issn-type":[{"value":"1533-0028","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Conversion Therapy With Encorafenib and Cetuximab for Chemo-Refractory BRAF V600E-Mutated Liver-Limited Colorectal Cancer Metastasis: The First Case Report","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2021.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}